Switching from Oral INVEGA® ER
| Dose Information |
|---|
Graph Information
Switching from Oral INVEGA® ER
Consistent with the INVEGA® Prescribing Information:
- The recommended dose of oral INVEGA ER for the treatment of schizoaffective disorder in adults is 6 mg administered once daily. Initial dose titration is not required. Some patients may benefit from lower or higher doses within the recommended dose range of 3 to 12 mg once daily. Dosage adjustment, if indicated, should occur only after clinical reassessment. Dose increases, if indicated, generally should occur at intervals of more than 4 days. When dose increases are indicated, increments of 3 mg/day are recommended. The maximum recommended dose is 12 mg/day.
Consistent with the INVEGA SUSTENNA® Prescribing Information:
- There are no systematically collected data to specifically address switching patients with schizophrenia or schizoaffective disorder from other antipsychotics to INVEGA SUSTENNA®, or concerning concomitant administration with other antipsychotics.
- Previous oral antipsychotics can be gradually discontinued at the time of initiation of treatment with INVEGA SUSTENNA®.
- Recommended initiation of INVEGA SUSTENNA® is with a dose of 234 mg followed by 156 mg one week later, both administered in the deltoid muscle.
- The initiation regimen (234 mg followed by 156 mg one week later, both in the deltoid muscle) rapidly attains steady-state paliperidone concentrations with no need for oral antipsychotic supplementation.
- Patients previously stabilized on different doses of oral INVEGA® ER can attain similar paliperidone
steady-state exposure during maintenance treatment with INVEGA SUSTENNA® monthly doses as depicted in the Table.
| Formulation | INVEGA® Exteneded-Release Tablet | INVEGA SUSTENNA® Injection |
|---|---|---|
| Dosing Frequency | Once Daily | Once every 4 weeks |
| Dose (mg) | 12 | 234 |
| 9 | 156 | |
| 6 | 117 | |
| 3 | 39-78* |
*Adjust dose based on tolerability and/or efficacy using available strengths. The 39 mg strength was not studied in the long-term schizoaffective disorder study.
- Administration: Each injection must be administered only by a healthcare professional. INVEGA SUSTENNA® is intended for intramuscular use only. Do not administer by any other route. Avoid inadvertent injection into a blood vessel.
INVEGA SUSTENNA® Prescribing Information [http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf]
Oral INVEGA® ER Prescribing Information [http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA-pi.pdf]